Factor XIa Tied to Benefit Beyond Stroke Prevention
Results from the OCEANIC-STROKE trial show that the investigational Factor XIa inhibitor, asundexian, not only reduces the recurrent ischaemic stroke risk, but when they do occur, they are less likely to be disabling or fatal. Medscape Medical News
Original Source
Read the full article at Medscape →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.